kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
397
JPY
-1
(-0.25%)
Mar 13, 3:30 pm JST
2.49
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.46
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
394 JPY 2.47 USD
Previous Close Mar 12
398 JPY 2.50 USD
High Mar 13, 9:18 am
397 JPY 2.49 USD
Low Mar 13, 10:24 am
389 JPY 2.44 USD
Volume
47,500
Trading Value
0.02B JPY 0.12M USD
VWAP
393.28 JPY 2.47 USD
Minimum Trading Value
39,700 JPY 249 USD
Market Cap
2.92B JPY 0.02B USD
Number of Trades
99
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
212
1-Year High Jun 12, 2025
3,785
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 1,016,100
Feb 27, 2026 0 1,005,900
Feb 20, 2026 0 1,001,100
Feb 13, 2026 0 1,008,800
Feb 6, 2026 0 993,400
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.